HDAC9 and B-cell non-Hodgkin lymphoma: An additional 20% of Eμ-HDAC9 mice either developed splenic B-cell lymphoma/leukemia (SBCL/L) or another hematological malignancy, such as histiocytic sarcoma (Table 1).